Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide
Daubert MA, Yow E, Dunn G, et al. Circulation: Heart Failure 2017;10:e004389.
What it found
No serious adverse events; blood pressure and heart rate stayed stable. At the highest dose, heart volumes fell slightly by the end of the infusion compared with placebo.
Limitations
Small, single-dose study with very short follow-up. Changes in heart volume are an intermediate measure.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.